AGP Executive Report

Last update: 5 hours ago

Digital Identity & Signatures: Shufti and Evrotrust are teaming up to link identity verification with Qualified Electronic Signatures in one onboarding flow across all 27 EU states, aiming to keep the legal “chain” intact under eIDAS. Crypto Regulation in Liechtenstein: Bitcoin Suisse (Europe) AG has received a MiCAR Crypto Asset Service Provider license from Liechtenstein’s FMA, giving it a clearer, passportable route to serve selected EEA markets. Stablecoin Rails Expand: OpenPayd also secured MiCA authorization in Malta, enabling fiat-to-stablecoin on/off-ramping across the EEA ahead of the July 1 transition deadline. Space Launch Delays: Open Cosmos says it missed an ITU launch deadline for its Ka-band constellation and is asking for an extension, citing force majeure after an Indian rocket failure. Health Tech (EU/EEA): The European Commission approved Trodelvy as first-line monotherapy for certain metastatic triple-negative breast cancer patients, including coverage for Norway, Iceland and Liechtenstein.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

No AGP Wire articles available right now.


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors


fallback image
6 hours ago

There is a Missing Link Between Identity Verification and Qualified Signatures in European Onboarding

EIN Presswire

fallback image
Jun. 23, 2026

Syncron Appoints Bianka Hay-Falk as Chief Human Resources Officer

GlobeNewswire, Inc.

fallback image
May 31, 2026

St. Kitts and Nevis enters New Space through historic life sciences mission with Switzerland

EIN Presswire

fallback image
Jun. 23, 2026

Five years of the ECB Survey of Monetary Analysts: evolution and insights

ECB - European Central Bank

fallback image
Mar. 30, 2026

Dental Laboratories Market Set to Reach USD 13.09 Billion by 2030 | MarketsandMarkets™

GlobeNewswire, Inc.

fallback image
Mar. 30, 2026

4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner

GlobeNewswire, Inc.

More press releases

Video Stories

YouTube video thumbnail: Ukraine Cuts off a Major Russian Supply Route
Play
Ukraine Cuts off a Major Russian Supply Route
YouTube video thumbnail: Red Heat Alerts Issued as Europe hit by Heatwave
Play
Red Heat Alerts Issued as Europe hit by Heatwave
Affinity Group Publishing Logo Showcase
Discover Affinity Group Publishing
YouTube video thumbnail:  Brexit 10 Years on: Is the UK Moving Closer to the EU Again?
Play
Brexit 10 Years on: Is the UK Moving Closer to the EU Again?
YouTube video thumbnail: European Parliament Backs Long-Awaited Digital Euro to Reduce US Dominance in Payments
Play
European Parliament Backs Long-Awaited Digital Euro to Reduce US Dominance in Payments

Video Title

Sign up for:

Technology Week Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Technology Week Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.